Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Avacta Group appoints Chief Scientific Officer for its Therapeutics Division

Stock MarketsSep 02, 2021 09:25
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.

By Samuel Indyk

Investing.com – Avacta Group PLC (LON:AVCT) has announced the appointment of Dr Fiona McLaughlin as Chief Scientific Officer of its Therapeutics Division, effective immediately.

Dr McLaughlin is an experienced oncology drug developer with over 25 years’ experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical development.

Dr McLaughlin has worked for various companies in the industry, including GlaxoSmithKline (LON:GSK) and BTG plc (now part of Boston Scientific (NYSE:BSX)).

Other roles include Head of Biology at TopoTarget, where she was responsible for the pre-clinical development of belinostat which gained approval from the US Food and Drug Administration (FDA) to treat peripheral T-cell lymphoma.

Dr McLaughlin’s most recent position was at Algeta (acquired by Bayer (DE:BAYGN)) where she was Vice-President of New Opportunities.

“I am delighted to join Avacta's Therapeutics Division at this pivotal time, as the company transitions to become a clinical stage development organisation,” said Dr McLaughlin. “I look forward to the opportunity of driving the strategic leadership of the company's therapeutics research and am excited by the potential of the pre|CISION™ and Affimer® platforms, to develop first and best-in-class oncology therapeutics, to ultimately provide patients with important new treatment options.”

Speaking about the appointment of Dr McLaughlin, Avacta Group CEO Dr Alastair Smith, said: “She brings a huge amount of experience, deep insight and strong leadership that will be major assets to Avacta in driving forward both the Affimer® and pre|CISION™ clinical and preclinical pipelines.”

At 09:17BST, shares in Avacta Group were trading higher by 1.9% at 136.75 pence per share.

Avacta Group appoints Chief Scientific Officer for its Therapeutics Division
 

Related Articles

Explainer: What is the
Explainer: What is the "metaverse"? By Reuters - Oct 20, 2021

LONDON (Reuters) - Facebook Inc (NASDAQ:FB), under fire from regulators and lawmakers over its business practices, is planning to rebrand itself...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email